The PROCLAIM study is the second major clinical study within the overarching EU-funded research project “Clinical impact through AI-assisted MS Care” (CLAIMS) (see also RECLAIM [link]).

PROCLAIM is a new prospective, multi-center study aimed at exploring how artificial intelligence (AI) can improve the care of people living with MS. The main goal is to determine if providing doctors with advanced, quantitative information from AI tools, on top of the standard clinical care, can lead to better treatment decisions and outcomes. The study is a collaborative effort sponsored by icometrix and co-sponsored by Charité – Universitätsmedizin Berlin, involving six clinical partners within the CLAIMS consortium.

For participants (people with MS), the study will investigate the use of a key medical device called icobrain mr (specifically its MS output, icobrain ms). This AI software analyses your brain Magnetic Resonance Imaging (MRI) scans to provide doctors with detailed, objective measurements of brain changes over time. Moreover, the participants are requested to employ the mobile app called icompanion. The icompanion app allows you to track and report your symptoms and well-being. By combining these novel tools with the regular standard-of-care at the clinical sites, researchers hope to show that AI-assisted care can make a meaningful difference in the long-term management of MS.